Otonomy raises $10 million for disorders of the inner and middle ear
This article was originally published in Scrip
Otonomy, which is developing therapies for disorders of the inner and middle ear, has raised a $10 million series A financing with Avalon Ventures. The proceeds will be used to fund the ongoing clinical trial of the US firm's lead product OTO-104 in Ménière's disease, toinitiate IND-enabling studies for its next product candidate OTO-203, and for early-stage development of a third programme, said the US firm.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.